

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Dixie Brands Inc. (the "Issuer").

Trading Symbol: DIXI.U

Number of Outstanding Listed Securities: 125,659,526 subordinate voting shares ("Shares")

Date: April 5, 2019

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer carries on the principal business of branding, marketing and licensing certain technology and product names related to THC-products, including "DIXIE™ ELIXIRS & EDIBLES", as well as full spectrum hemp oil derived human and animal dietary supplements through the brands "ACESO WELLNESS" and "THERABIS" in the United States, Canada, Mexico, Australia, New Zealand and Latin America.

Since the date of the Issuer's most recent Form 7, the Issuer has entered into a definitive joint venture agreement with Choice Labs (the "Choice JV"). Under the terms of the Choice JV, the Issuer granted a license to use the Issuer's intellectual property, including its proprietary formulations and preparation methods, as well as associated trademarks, in the State of Michigan. Choice will manufacture and sell Issuer's portfolio of products in Michigan. Please see the news releases dated February 6, 2019 and March 15, 2019.

The Issuer has entered into a definitive joint venture agreement with Khiron Life Sciences Corp. ("Khiron JV") for the manufacture and distribution of cannabis-infused products in the Latin America market. The Issuer will license its intellectual property, including the trademarks of its brand portfolio and the proprietary recipes, processes and production methods to the joint venture entity and will also manufacture and distribute Khiron Life Sciences Corp.'s Kuida® band of cannabidiol (CBD)-based cosmeceuticals in the United States. Please see the news releases dated January 30th, 2019 and March 14th, 2019.

The Issuer acquired a further 25% stake in Therabis LLC from Rose Capital Fund I, LP, as announced in the news release dated January 14th, 2019. The Issuer now owns an 85% stake in Therabis LLC.

2. Provide a general overview and discussion of the activities of management.

The Issuer's management is currently negotiating various agreements to expand its footprint in the United States and internationally.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Since the date of the Issuer's most recent Form 7, the Issuer's pet wellness subsidiary, Therabis LLC, has created a new product, "Calm and Quiet", which is a hemp-based soft chew for cats. Please see the news release dated February 25th, 2019.

4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

Not applicable.

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

The Issuer executed two joint venture agreements as discussed above in Section 1. The parties to each joint venture agreement are not Related Persons.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

Not applicable.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

Not applicable.

8. **Describe the acquisition of new customers or loss of customers.**

Not applicable.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

Not applicable.

10. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None.

11. **Report on any labour disputes and resolutions of those disputes if applicable.**

None.

12. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

13. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

The Issuer did not incur or repay any indebtedness other than in the normal course of operations.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Shares	781,250	Issued as advisory fee with respect to the Khiron JV.	N/A
Warrants	Nil.	N/A	N/A
Options	4,000,000 options exercisable for Shares	Issued to management, employees and consultants	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The most significant trends and uncertainties which management expects could impact its business and financial condition are the changing legal and regulatory regime which regulates the production and sale of cannabis and cannabis related products in the United States and other jurisdictions. See Section 17 – Risk Factors in the Issuer's CSE Form 2A Listing Statement dated November 23, 2018 available on www.sedar.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 5, 2019.

C.J. Chapman
Name of Director or Senior Officer

(signed) C.J. Chapman
Signature

General Counsel
and Corporate Secretary
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/D
Dixie Brands Inc.	March 31, 2019	2019/04/04
Issuer Address		
4990 Oakland Street		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Denver, CO 80239	(---)-----	(702)-224-6936
Contact Name	Contact Position	Contact Telephone No.
C.J. Chapman	General Counsel	(702)-224-6936
Contact Email Address	Web Site Address	
cchapman@dixiebrands.com	http://dixieelixirs.com/	